The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high‐quality lung cancer screening
More than a decade has passed since researchers in the Early Lung Cancer Action Project and the National Lung Screening Trial demonstrated the ability to save lives of high-risk individuals from lung cancer through regular screening by low dose computed tomography scan. The emergence of the most recent findings in the Dutch-Belgian lung-cancer screening trial (Nederlands-Leuvens Longkanker Screenings Onderzoek [NELSON]) further strengthens and expands on this evidence. These studies demonstrate the benefit of integrating lung cancer screening into clinical practice, yet lung cancer continues to lead cancer mortality rates in the United States. Fewer than 20% of screen eligible individuals are enrolled in lung cancer screening, leaving millions of qualified individuals without the standard of care and benefit they deserve. This article, part of the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) strategic plan, examines the impediments to successful adoption, dissemination, and implementation of lung cancer screening. Proposed solutions identified by the ACS NLCRT Implementation Strategies Task Group and work currently underway to address these challenges to improve uptake of lung cancer screening are discussed. PLAIN LANGUAGE SUMMARY: The evidence supporting the benefit of lung cancer screening in adults who previously or currently smoke has led to widespread endorsement and coverage by health plans. Lung cancer screening programs should be designed to promote high uptake rates of screening among eligible adults, and to deliver high-quality screening and follow-up care.
Authors
- Claudia I. Henschke (ORCID: https://orcid.org/0000-0002-6085-5305)
- Robert Allen Smith (ORCID: https://orcid.org/0000-0003-3344-2238)
- Lillie D. Shockney (ORCID: https://orcid.org/0000-0001-5625-3881)
- Joelle T. Fathi (ORCID: https://orcid.org/0000-0002-6637-0931)
- Bruce Pyenson (ORCID: https://orcid.org/0000-0003-0416-9391)
- Charles S. White (ORCID: https://orcid.org/0000-0002-9789-7648)
- Carey C. Thomson (ORCID: https://orcid.org/0000-0002-5861-0683)
- James L. Mulshine (ORCID: https://orcid.org/0000-0002-4648-9177)
- Ella A. Kazerooni (ORCID: https://orcid.org/0000-0001-5859-8744)
- A.M. Barry (ORCID: https://orcid.org/0000-0003-4999-3923)
- Peter J. Mazzone (ORCID: https://orcid.org/0000-0003-2121-0595)
- Renda Soylemez Wiener (ORCID: https://orcid.org/0000-0001-7712-2135)
- Jane J. Kim (ORCID: https://orcid.org/0000-0002-9892-9170)
- Grant M. Greenburg
Institutions
- Boston University (US)
- University of Maryland, Baltimore (US)
- Rush University Medical Center (US)
- American Cancer Society (US)
- Mount Auburn Hospital (US)
- Cleveland Clinic (US)
- Harvard University (US)
- Johns Hopkins University (US)
- University of Washington (US)
- Johns Hopkins Medicine (US)
- VA Boston Healthcare System (US)
- Lehigh Valley Health Network (US)
- Phoenix VA Health Care System (US)
- Michigan Medicine (US)
- Go2 for Lung Cancer (US)
- Durham VA Medical Center (US)
- Milliman (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1002/cncr.34621
- Citations
- 6
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- U.S. Department of Veterans Affairs
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Daiichi-Sankyo
- Genentech
- Foundation Medicine